Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948909 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
- 20
- Study locations
NCT00948909: Completed Phase 2 study of Alzheimers Disease, sponsored by AbbVie (prior sponsor, Abbott).
NCT00948909 is a Phase 2 study of Alzheimers Disease that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 274 participants, below the 3,924-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00948909, a Phase 2 study of Alzheimers Disease, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a efficacy and safety study evaluating new treatment for subjects with mild to moderate Alzheimer's Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABT-126
- DRUG donepezil
Study Locations (20)
Other
- Site Reference ID/Investigator# 22944 - Pleven
- Site Reference ID/Investigator# 22942 - Plovdiv
- Site Reference ID/Investigator# 22945 - Sofia
- Site Reference ID/Investigator# 22946 - Sofia
- Site Reference ID/Investigator# 20276 - Litoměřice
- Site Reference ID/Investigator# 20273 - Pilsen
- Site Reference ID/Investigator# 20274 - Prague
- Site Reference ID/Investigator# 20272 - Prague
- Site Reference ID/Investigator# 20701 - Prague
- Site Reference ID/Investigator# 23625 - Bratislava
- Site Reference ID/Investigator# 23624 - Bratislava
- Site Reference ID/Investigator# 23622 - Michalovce
- Site Reference ID/Investigator# 23942 - Rimavská Sobota
- Site Reference ID/Investigator# 20267 - Belville
- Site Reference ID/Investigator# 20266 - Cape Town
- Site Reference ID/Investigator# 20261 - Durban
- Site Reference ID/Investigator# 21682 - George
California
- Site Reference ID/Investigator# 19904 - Fresno
Florida
- Site Reference ID/Investigator# 23025 - West Palm Beach
Indiana
- Site Reference ID/Investigator# 19905 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT00948909 record still lists
NCT00948909 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, below the 3,924-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00948909 names 20 study sites across 4 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00948909 about?
NCT00948909 is a clinical study titled "Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease". This is a efficacy and safety study evaluating new treatment for subjects with mild to moderate Alzheimer's Disease.
What is the current status of trial NCT00948909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2009-10. Estimated completion is 2010-11.
What conditions does trial NCT00948909 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00948909?
The interventions under investigation include: Placebo (DRUG), ABT-126 (DRUG), donepezil (DRUG).
Who is sponsoring clinical trial NCT00948909?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00948909 being conducted?
This trial has 20 study locations across California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00948909's enrollment target sits among peer trials
274 45th of 147 higher than 103 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia